22 AUDITOR’S REMUNERATION For the year ended 30 June 2024 $ For the year ended 30 June 2023 $ Amounts received or due and receivable by the Company’s auditors Grant Thornton for: - Auditing the statutory financial report of the Parent company of the Group and auditing the statutory financial reports of any controlled entity. 118,965 122,460 118,965 122,460 23 RELATED PARTY DISCLOSURES Other related party transactions (A) WHOLLY OWNED GROUP TRANSACTIONS Details of interests in controlled entities are set out in Note 24. (B) ULTIMATE PARENT COMPANY INOVIQ Limited is the ultimate legal Australian holding Company. (C) TRANSACTIONS WITH OTHER RELATED PARTIES Kidder Williams, a Corporate Advisory and Investment Banking services firm owned by INOVIQ Chairman David Williams, received Corporate Advisory fees from INOVIQ during the year totalling $70,000. Kidder Williams also advised INOVIQ on its June 2024 capital raise, receiving $189,063 for services provided in conjunction with the placement component of the raising. The Company does not have any other transactions with other related parties. 24 CONTROLLED ENTITIES Consolidated entities of INOVIQ Ltd Country of Incorporation Equity Interest held % 30 June 2024 30 June 2023 Sienna Cancer Diagnostics Limited Australia 100 100 INOVIQ Inc. (formerly Sienna Cancer Diagnostics Inc.) U.S.A. 100 100 Melbourne Diagnostics Pty Ltd Australia 100 100 25 EVENTS SUBSEQUENT TO BALANCE DATE The following announcements were made via the ASX announcement platform since the end of the reporting period: – On 5 July 2024, the Company announced the completion of the Share Purchase Plan (SPP) component of the capital raise announced on 12 June 2024. The SPP raised $2.379m (gross) post 30 June 2024 and issued 2,378,914 listed options on 9 July 2024; – 6,749,999 listed options attaching to the June 2024 placement were also issued on 9 July 2024; and – On 20 August 2024, the Company announced that it had further validated its NEURO-NET technology for isolation of brain-derived exosomes in Parkinsons’ Disease. At the date of this report, other than that outlined above, there have been no matters or circumstances that have arisen since the end of the period which significantly, or may significantly effect: – The Group’s operations in future years; – The results of those operations in future years; or – The Group’s state of affairs in future years. Notes to the Financial Statements continued for the year ended 30 June 2024 58 INOVIQ Limited
RkJQdWJsaXNoZXIy MjE2NDg3